Daxor Corporation

323 articles about Daxor Corporation

• Daxor to Present at the H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Sciences Conference which is being held from March 9th to 10th through a virtual format with on-demand video presentations.

• Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020

  2/26/2021

  Daxor Corporation(NYSE MKT: DXR) The global leader in blood volume technology today filed its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2020.

• DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)

  2/19/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been officially recognized as meeting all the requirements of ISO 13485; Medical Devices, Quality Management System Certification ensuring the consistent design, development, production, installation, and delivery for the Blood Volume Analyzer (BVA-100®) system is safe for its intended purpose.

• DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER

  2/5/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the Center for Advancing Point of Care Technologies (CAPCaT), a program run by the Massachusetts Medical Device Development Center (M2D2)

• New Research Demonstrates the Clinical Utility with Daxor’s Blood Volume Analyzer (BVA-100®) in Critical Care

  2/4/2021

  Daxor Corporation(NYSE MKT: DXR) the global leader in blood volume measurement technology, today announces new data from the University of Hawaii John A. Burns School of Medicine showing the BVA-100 blood test accurately and uniquely reflects blood volume status after massive blood transfusion, a key metric for this procedure, while traditional clinical metrics fail in 80% of the cases analyzed.

• DAXOR CORPORATION TO EXHIBIT AT THE SOCIETY FOR CRITICAL CARE MEDICINE 50TH CONGRESS VIRTUAL EVENT

  1/26/2021

  NEW DATA SCHEDULED FOR PRESENTATION ON DAXOR’S BVA-100 ® BLOOD TEST NEW YORK, Jan. 26, 2021

• DAXOR ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH L1 ENTERPRISES GOVERNMENT DISTRIBUTOR

  1/13/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), announces today that it has signed a new distribution agreement with L1 Enterprises, a leading provider of medical equipment and supplies to the government marketplace including the Department of Defense (DOD), Department of Veterans Affairs (

• Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference

  1/8/2021

  Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the inaugural H.C. Wainwright BioConnect Investment Conference

• Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

  12/10/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces additional acquisitions of Daxor’s BVA-100® Blood Volume Analyzer at major medical centers across the U.S.

• Daxor Corporation to Present at the 13th Annual LD Micro Main Event 2020

  12/9/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President and Chief Executive Officer, will present at the virtual 2020 LD MicroCap Main Event on December 14, 2020 at 10:40 AM ET in Track One: Top Dollar.

• THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY

  11/19/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Wake Forest Baptist Health will participate in an ongoing trial to treat patients hospitalized with COVID-19 utilizing Daxor's BVA-100 (Blood Volume Analyzer, "BVA") technology.

• Oregon Health & Science University Joins Multicenter Covid-19 BVA-100® Study

  10/29/2020

  COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor’s Blood Volume Analysis Technology

• Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl

  10/12/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President and Chief Executive Officer, will present at the virtual 2020 MicroCap Rodeo Best Ideas Bowl on Tuesday, October 13th at 3:00 PM ET. Mr. Feldschuh will provide a company overview and discuss key highlights including new researc

• New Research Shows Daxor’s BVA-100® Blood Test Provides Unique Benefit in Detecting Anemia and Heart Failure Risk, Presented at the Heart Failure Society of America Meeting 2020

  10/6/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data presented during the Heart Failure Society of America’s Annual Scientific Meeting focused on the use of Daxor’s BVA-100® blood test for uniquely measuring anemia.

• New Research Demonstrates Daxor BVA-100® Blood Test Provides “Extremely Cost-Effective” Improvement in Patient Life Span at the Heart Failure Society of America Annual Scientific Meeting 2020

  10/5/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces compelling new data demonstrating further beneficial use of Daxor’s blood volume analysis technology presented during the Heart Failure Society of America’s Virtual Annual Scientific Meeting 2020.

• New Data Released from the Mayo Clinic Utilizing Daxor’s BVA-100® Test Highlights Value of Daxor’s Diagnostic at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020

  10/2/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data from the Mayo Clinic showing that Daxor’s Blood Volume diagnostic test utilizing its BVA-100 device is clinically superior to the common proxy marker of weight loss to measure progress in heart failure (HF) treatment.

• Daxor Corporation to Exhibit and Showcase Compelling New Data at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020 on the Value of BVA-100®

  9/28/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be exhibiting and showcasing new data at the Heart Failure Society of America’s (HFSA) Virtual Annual Scientific Meeting 2020 taking place from September 30th - October 6th, 2020. The Company will host a booth and will be available online throughout the e

• Daxor to Present at the Inaugural Sepsis Alliance Summit

  9/15/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be participating in the inaugural Sepsis Alliance Summit.

• Daxor to Present at H.C. Wainwright 22nd Annual Global Investment Conference

  9/10/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Michael Feldschuh, Daxor’s President & Chief Executive Officer, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020, at 2:00 PM ET. The Company will present virtually and provide updates about re

• Daxor Corporation to Present at the LD 500 Virtual Investor Conference

  8/31/2020

  Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that it will be presenting at the LD 500 Virtual Investor Conference scheduled to take place from September 1-4, 2020.